Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Norfin in oncological practice].

N A Osipova, V V Petrova, G A Novikov

    Anesteziologiia I Reanimatologiia
    |July 1, 1992
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Prediction of unfavorable outcome of acute decompensation of diabetes mellitus.

    Diabetology & metabolic syndrome·2025
    Same author

    Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications.

    Molecular genetics & genomic medicine·2024
    Same author

    [Prospects of qualitative and quantitative assessment of bowel perfusion by fluorescent angiography with indocyanine green in colorectal surgery. First experience].

    Khirurgiia·2024
    Same author

    Melatonin and its bioisosteres as potential therapeutic agents for the treatment of retinopathy of prematurity.

    Chemical biology & drug design·2024
    Same author

    Enalaprilat as a new means of preventing the development of retinopathy of prematurity.

    Biomeditsinskaia khimiia·2023
    Same author

    Analysis of mutations spectrum in the ATP7B gene in patients with Wilson disease using massively parallel sequencing.

    Klinicheskaia laboratornaia diagnostika·2022

    Norphin, a synthetic opiate, effectively manages cancer pain and serves as an anesthetic. It offers comparable efficacy to morphine with fewer adverse reactions, making it a valuable option for chronic pain and surgical procedures.

    Area of Science:

    • Anesthesiology
    • Pharmacology
    • Oncology

    Background:

    • Cancer pain management and anesthesia are critical in patient care.
    • Synthetic opiate agonist-antagonists offer potential therapeutic advantages.
    • Norphin (buprenorphin) is a synthetic opiate agonist-antagonist with analgesic properties.

    Purpose of the Study:

    • To evaluate norphin as an analgesic in general anesthesia for cancer patients.
    • To assess norphin's efficacy in postoperative analgesia.
    • To investigate norphin's utility in treating chronic pain syndrome in cancer patients.

    Main Methods:

    • A study involving 297 cancer patients.
    • Norphin used as an analgetic component in general anesthesia.
    • Modified neuroleptanalgesia with norphin, diazepam, droperidol, and N2O compared to fentanyl-based neuroleptanalgesia.

    Related Experiment Videos

  • Sublingual administration of norphin for chronic pain management.

    • Main Results:

    • Norphin-based anesthesia provided better prevention of surgical trauma and greater stability in circulatory, metabolic, and stress hormone parameters compared to fentanyl-based anesthesia.
    • Norphin-based anesthesia was less manageable and associated with prolonged central nervous system depression.
    • Sublingual norphin demonstrated good results in treating long-lasting, intensive chronic pain in incurable cancer patients.
    • Norphin showed comparable efficacy to morphine but with significantly fewer severe adverse reactions.

    Conclusions:

    • Norphin is an effective analgesic for cancer patients undergoing general anesthesia and for managing chronic pain.
    • While norphin-based anesthesia offers benefits, its manageability and potential for prolonged CNS depression require consideration.
    • Sublingual norphin presents a viable alternative to morphine for chronic cancer pain, offering comparable efficacy with an improved safety profile.